Manuel de Jesus Diaz Verduzco

Prof. Manuel de Jesus Diaz Verduzco

Hospital Regional Dr. Manuel Cárdenas De la Vega., Institute for Social Security and Services for State Workers, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2022 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
FCFabián Caro
Fabián Caro
Ivette Buendia-RoldanIvette Buendia-Roldan
Ivette Buendia-Roldan
LNLorena Noriega-Aguirre
Lorena Noriega-Aguirre
MAMaría L. Alberti
María L. Alberti
AAAlexandre Amaral
Alexandre Amaral
MSMoises Selman
Moises Selman

RFRicardo Figueiredo
Ricardo Figueiredo
NDNathalia Filgueiras Vilaça Duarte
Nathalia Filgueiras Vilaça Duarte
DCDaniela Carla Barbosa Campos
Daniela Carla Barbosa Campos
MVManuel de Jesus Diaz Verduzco
Manuel de Jesus Diaz Verduzco
ÁMÁngel Alemán Márquez
Ángel Alemán Márquez
ARAdalberto Sperb Rubin
Adalberto Sperb Rubin
Delayed initiation of effective antifibrotic therapy in patients with interstitial lung diseases (ILD) may influence the progression and outcome of the disease. This study analyzes the differences in the journey of patients with ILD in the Brazilian and Mexican health systems. An evaluative study was conducted in reference centers for interstitial lung diseases in Brazil and Mexico with a panel of four specialists. The patient’s journey in both countries begins when the patient seeks medical care after observing a chronic respiratory symptom. In both countries, due to diagnostic complexity, these patients arrive at ILD referral centers at an advanced stage of the disease. Once diagnosis is established, the treatment onset differs between Mexico and Brazil. In Brazil, access to antifibrotic drugs through the public health system has been a significant challenge, and their cost makes them unaffordable for most people. This situation forces medical specialists to provide only supportive care to patients until these drugs can be accessed. In Mexico, antifibrotics have been available in health sectors since 2018. Brazil and Mexico have several similarities regarding the initial journey of the patient due to diagnosis difficulties. Still, the outcome tends to be different due to a difference in access to treatment with antifibrotics. For this reason, advancing health policies that ensure proper treatment for patients with ILD is crucial for the sustainability and reliability of the health system.

25 February 2006
Verified
Journal Article
Closed access
DCDavid López Del Castillo-Sánchez
David López Del Castillo-Sánchez
ESEnrique Sabag-Ruiz
Enrique Sabag-Ruiz
MVManuel de Jesus Diaz Verduzco
Manuel de Jesus Diaz Verduzco
MMMario Alonso Monzón-Vega
Mario Alonso Monzón-Vega